Rapport Therapeutics Reports Q4 Net Loss Of $19.98 Mln

(RTTNews) - Rapport Therapeutics, Inc. (RAPP) Tuesday reported net loss of $19.98 million or $0.57 per share for the fourth quarter higher than $13.52 million or $8.01 per share loss in the same quarter a year ago.

Additionally, the company said it expects to report topline data from the Phase 2a study of RAP-219 in patients with refractory focal epilepsy in the third quarter of 2025.

Rapport also plans to initiate a Phase 2a study of RAP-219 in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027.

As on December 31, 2024, the company had $305.3 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026.